Research Funding Lacking for Cancers With High Mortality Rates


Researchers found disparities in cancer research funding from the National Cancer Institute (NCI) and nonprofit organizations, as reported in JCO Oncology Practice. The study evaluated funding for solid tumors and hematologic malignancies from 2015 to 2018. The combined NCI-nonprofit budget was $13.66 billion, with breast cancer, leukemia, and lung cancer receiving the most funding. Some cancers, such as endometrial and cervical cancer, received significantly less funding. Funding correlated well with disease incidence but not mortality rate. Well-funded cancers included breast cancer, leukemia, lymphoma, and prostate cancer, while melanoma, colorectal cancer, and lung cancer were underfunded. Funding also correlated differently between Black and White patients. The researchers concluded that less funding correlates with fewer clinical trials for a particular disease.

Source link

error: Content is protected !!